TYP ASX News

17 December 2024

Positive interim results in Phase 2a TRP-8802 IBS trial

Tryptamine Therapeutics announces positive interim results in Phase 2a IBS trial.

Tryptamine Therapeutics IBS Clinical Trial Psilocybin Biopharmaceuticals

Posted on: 17/12/2024

15 December 2024

Phase 1b extension results meet study objectives

Tryptamine Therapeutics completes successful Phase 1b study on TRP-8803 in obese subjects.

Tryptamine Therapeutics Psilocin Clinical Trials Biopharmaceuticals Stock Market News

Posted on: 15/12/2024

18 November 2024

Phase 1b determines optimal parameters for TRP-8803 use

Tryp Therapeutics completes Phase 1b study of TRP-8803, advancing to Phase 2 trials.

Tryp Therapeutics Psilocin Phase 1b Study Clinical Trials Biopharmaceutical

Posted on: 18/11/2024

11 August 2024

Positive Phase 2a fibromyalgia results across all patients

Tryp Therapeutics reports 100% patient improvement in Phase 2a fibromyalgia trial.

Tryp Therapeutics Fibromyalgia Clinical Trial Psilocybin Stock Market News

Posted on: 11/08/2024